Scilight Press

Author Information

Received: 26 Jan 2025 | Accepted: 28 Jan 2025 | Published: 01 Mar 2025

Abstract

Keywords

Diabetic kidney disease | MRA | Proteinuria

References 

• 1.
  Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2021—Results; Institute for Health Metrics and Evaluation: Seattle, WA, USA, 2024. Available online: https://vizhub.healthdata.org/gbd-results/ (accessed on 10 January 2025).
• 2.
  Chertow, G.M.; Correa-Rotter, R.; Eckardt, K.U.; et al. Projecting the Clinical Burden of Chronic Kidney Disease at the Patient Level (INSIDE CKD): A Microsimulation Modelling Study. EClinicalMedicine 2024, 72, 102614.
• 3.
  Aggarwal, R.; Ostrominski, J.W.; Vaduganathan, M. Prevalence of Cardiovascular-Kidney-Metabolic Syndrome Stages in US Adults, 2011–2020. JAMA 2024, 331, 1858–1860.
• 4.
  Rossing, P.; Caramori, M.L.; Chan, J.C.; et al. Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2022, 102 (Suppl. 5), S1–S127.
• 5.
  Naaman, S.C.; Bakris, G.L. Diabetic Nephropathy: Update on Pillars of Therapy Slowing Progression. Diabetes Care 2023, 46, 1574–1586.
• 6.
  Tuttle, K.R.; Wong, L.; St. Peter, W.; et al. Moving from Evidence to Implementation of Breakthrough Therapies for Diabetic Kidney Disease. Clin. J. Am. Soc. Nephrol. 2022, 17, 1092–1103.
• 7.
  Agarwal, R.; Kolkhof, P.; Bakris, G.; et al. Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. Eur. Heart J. 2021, 42, 152–161.
• 8.
  Bakris, G.L.; Agarwal, R.; Chan, J.C.; et al. Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial. JAMA 2015, 314, 884–894.
• 9.
  Bakris, G.L.; Agarwal, R.; Anker, S.D.; et al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N. Engl. J. Med. 2020, 383, 2219–2229.
• 10.
  Pitt, B.; Filippatos, G.; Agarwal, R.; et al. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. N. Engl. J. Med. 2021, 385, 2252–2263.
• 11.
  Agarwal, R.; Filippatos, G.; Pitt, B.; et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: The FIDELITY pooled analysis. Eur. Heart J. 2022, 43, 474–484.
• 12.
  Agarwal, R.; Joseph, A.; Anker, S.D.; et al. Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial. J. Am. Soc. Nephrol. 2022, 33, 225–237.
• 13.
  Vardeny, O.; Vaduganathan, M.; Claggett, B.L.; et al. Finerenone, Serum Potassium, and Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction. JAMA Cardiol. 2025, 10, 42–48.
• 14.
  Green, J.B.; Mottl, A.K.; Bakris, G.; et al. Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE). Nephrol. Dial. Transplant. 2023, 38, 894–903.
• 15.
  Heerspink, H.J.L.; Agarwal, R.; Bakris, G.L.; et al. Design and baseline characteristics of the Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease (FIND-CKD) randomized trial. Nephrol. Dial. Transplant. 2024, 40, 308–319. https://doi.org/10.1093/ndt/gfae132.
• 16.
  Heerspink, H.J.L.; Birkenfeld, A.L.; Cherney, D.Z.I.; et al. Rationale and design of a randomised phase III registration trial investigating finerenone in participants with type 1 diabetes and chronic kidney disease: The FINE-ONE trial. Diabetes Res. Clin. Pract. 2023, 204, 110908.
• 17.
  American Diabetes Association Professional Practice Committee. 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025. Diabetes Care 2025, 48 (Suppl. 1), S239–S251.